Science1 distinct publisher3 min readPublished
The World Health Organization counts one in six infections as drug resistant, and a growing body of research argues that heat and chemical stress help resistance genes persist and travel. The size of that contribution is still unmeasured.
The Scientist · Science desk
Compiled by The ScientistSomething wrong?How this is made
Resistance genes are older than the drug industry. Competing microbes in soil, water and even air already manufacture antimicrobial compounds and the defences against them, as ordinary ecological business [5]. Bacteria pass those defences sideways, between individuals and even across species, with no parent-offspring step involved [6]. A course of antibiotics does not invent that hardware. It thins the population around the cells that already carry it, and those cells repopulate [7]. So any environmental variable that raises mutation rates, or speeds the sideways traffic, is acting on the same pathway a prescription acts on, one compartment upstream. As logic, that holds.
The material offers direction, not magnitude. Tavella's phrasing is careful and modest: climate change "can modify" the environmental, ecological and social conditions that let resistant organisms emerge, persist, move and reach hosts, while antimicrobial use remains a central driver [4]. It says which way the effect runs, not how large it is. Nothing in the reporting supplied here estimates what share of resistant infections traces to warming [14]. The mortality figure has a related softness: it is given as deaths associated with bacterial resistance rather than deaths caused by it [2], and those are not the same quantity.
The prevalence pair invites the same care. A third divided by a sixth is two, so the worst-affected areas are running at twice the global share [13]. The thing that ratio does not tell you is which areas, or which infections sit in the denominator, and those are the first two questions anyone testing the climate hypothesis would need answered, because the natural experiment here is two hospitals with matched prescribing policy in different catchments.
My view, with its conditions attached: the mechanism is credible enough to fund as a measurement programme and far too unsized to re-cut a stewardship budget around. Prescribing is the compartment a hospital can count and change inside a quarter. Water tables and farm soil are not, which is both why the reframing deserves attention and why it needs a number before it becomes a line item.
Two patient histories in the Eos feature mark out who this reaches. Ella Balasa, born with cystic fibrosis, took antibiotics often enough that the microbes lodged in her scarred lungs stopped responding, and in 2019 her lung function fell into the teens against a normal of 80% or higher [11]. Bhakti Chavan was diagnosed with drug-resistant tuberculosis after finishing a master's degree in Mumbai, with no previous history of the disease, and was treated for eight months [12]. Balasa's resistance traces back through her own prescription record, while Chavan's arrived from somewhere outside it [15]; mapping those somewhere-elses is the work the climate hypothesis is asking for.
Ranked by verification strength, evidence, and original report placement.
Ronan Adler Tavella, an environmental health scientist at the Antimicrobial Resistance Institute at the Federal University of Sao Paulo, told Eos by email that antimicrobial use remains one of the central drivers of AMR, but that climate change can modify the environmental, ecological and social conditions that allow resistant microorganisms and resistance genes to emerge, persist, move, and reach humans, animals and ecosystems.
A growing body of research suggests a changing climate is another factor in the rise of antimicrobial resistance, alongside antibiotic misuse.
The World Health Organization says one in six infections is drug resistant, and that in some areas the share is one in three.
In 2021 the WHO estimated that bacterial antimicrobial resistance was associated with more than 4.7 million deaths around the world.
Drivers of rising antimicrobial resistance include the misuse and overprescription of antibiotics in humans and their use to control disease in livestock and agricultural crops.
Antimicrobial resistance genes occur in nature because microbial groups compete ecologically: microbes in soil, water and even air produce antimicrobial compounds and resistance mechanisms aimed at competitors.
Distinct publishers with included, body-backed reporting in this cluster.
1 article · September 1, 2026
Follow any of these and your For You feed starts watching them — no settings page required.
science
Stewardship is aimed at the wrong half: rich countries use the resistance drugs, LMICs need them1 distinct publisher
science
A phage kinase with no target list: EMBL finds one enzyme that breaks several bacterial defences1 distinct publisher
science
Half the resistance genes in livestock manure also show up in 875 wild farm mice1 distinct publisher
product
A blood-draw robot clears the FDA at 1m49s a stick. The missing number is per supervisor1 distinct publisher
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
WHO numbers, interview mechanisms
The two figures doing the heaviest work — one in six infections, 4.7 million associated deaths — are WHO's and are reported cleanly, though without naming the report they come from. Everything downstream is interview material: an environmental health scientist by email, an infectious disease physician on the phone, a WHO technical officer. Good attribution, thin documentation. Not one study is cited for the climate half of the argument.
Nothing here is being deployed
There is no product, program or rollout in this reporting to count. Adoption for a story like this would look like surveillance systems coming online, stewardship rules taking effect, or new drugs entering formularies — Eos reports none of those, only two patients' treatment histories. We are not going to manufacture an uptake number from clinical anecdote.
The framing outruns the arithmetic
"Climate change is making it worse" is a magnitude claim, and no magnitude appears anywhere in the piece. What the reporting actually establishes is directional and plausible: stress raises mutation rates, warming shifts where resistant microbes persist and travel, India is hot and resistant at once. The gap sits in the packaging rather than the sourcing — Tavella is explicit that antimicrobial use remains a central driver, and the reporting never claims otherwise.
Institutionally aligned, commercially clean
The voices are people whose standing rises with the salience of resistance: a technical officer inside WHO's AMR department, a scientist at an institute named for the problem. That is alignment worth noting. But nobody in this story is selling anything — no drug candidate, no diagnostic, no platform, no stated funding round — and the two patients quoted carry the emotional weight with no stake at all. Mild pressure toward urgency, no pressure toward a purchase.
Firm numbers, unsized mechanism
Split the story and confidence splits with it. The burden figures are traceable to WHO and safe to repeat. The climate mechanism rests on two researchers in a single article that no other outlet in our coverage corroborates, and the one place a number would settle the argument is the one place the reporting is silent.